ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Overweight and obesity in adults: Health consequences

Overweight and obesity in adults: Health consequences
Literature review current through: Jan 2024.
This topic last updated: Jun 27, 2023.

INTRODUCTION — The mortality and morbidity associated with overweight or obesity have been known to the medical profession for more than 2000 years [1]. Overweight refers to a weight above the "normal" range. Although imperfect, calculation of the body mass index (BMI, defined as the weight in kilograms divided by height in meters squared) (calculator 1) is widely accepted for the determination of underweight, normal weight, overweight, and obesity. Overweight is defined as a BMI of 25 to 29.9 kg/m2, obesity as a BMI of >30 kg/m2, and severe obesity is defined as a BMI >40 kg/m2.

Adult obesity is associated with a striking reduction in life expectancy, particularly among those who develop obesity when they are young (eg, <40 years old) [2]. It has been suggested that the steady rise in life expectancy seen during the past two centuries may end because of the increasing prevalence of obesity [3]. Individuals with obesity who also smoke have a substantially greater decrease in life expectancy compared with those without obesity who smoke and those with obesity who do not smoke [4].

The health hazards associated with obesity are reviewed here. Prevention and/or treatment of health consequences of obesity are an important component of the obesity management. The prevalence of and therapy for obesity, as well as the evaluation of the overweight patient, are discussed elsewhere:

(See "Obesity in adults: Overview of management".)

(See "Obesity in adults: Prevalence, screening, and evaluation".)

(See "Obesity in adults: Drug therapy".)

MORTALITY

Relationship between weight and mortality — In general, greater body mass index (BMI) (calculator 1) is associated with increased all-cause and cardiovascular mortality (figure 1) [5]. The risk profile can be expressed as a J-shaped curve with greater mortality at BMI <20 kg/m2 and >25 kg/m2. The risk is progressive in the high BMI range and particularly notable for those with severe obesity [6]. Excess body weight contributed to four million deaths globally in 2015 and more than 320,000 deaths in the United States in 2014 [7].

Weight gain from youth to adulthood as well as stable obesity in adulthood are associated with increased risk of mortality [8]. Among never smokers, compared with individuals of healthy weight (BMI 18.5 to 24.9 kg/m2), life expectancy from age 40 years was 4.2 years shorter in males with obesity (BMI ≥30.0 kg/m2) and 3.5 years shorter in women with obesity [9].

A number of large epidemiologic studies have evaluated the relationship between obesity and mortality [6,10-20]. In a meta-analysis of 230 cohort studies including over 30 million individuals, both obesity and overweight were associated with an increased risk of all-cause mortality [21].

Being overweight also appears to be associated with increased mortality in some [12,17,22,23] but not all [19,24,25] studies. Evidence for excess mortality with increasing BMI includes the following:

In an analysis of 57 prospective studies (894,000 European and North American adults followed for a mean of eight years), mortality was lowest among those with a BMI between 22.5 to 25 kg/m2, with a 30 percent increase in overall mortality for each 5 kg/m2 increase in BMI (figure 1) [17]. Similar results were seen in a second study [22]. The figure (figure 1) shows that increasing BMI for individuals of European ancestry has a curvilinear relation to mortality. The shape of the relationship may be different for different ethnicities, but the association remains [26-28].

Other evidence that overweight and obesity are associated with excess mortality comes from a meta-analysis of 239 prospective studies of BMI and mortality in 10,625,411 participants in Asia, Australia and New Zealand, Europe, and North America [5]. For the four populations combined, all-cause mortality risk increased with increasing BMI (kg/m2) category: hazard ratio (HR) 1.07 for BMI 25.0 to <27.5, 1.20 for BMI 27.5 to <30.0, 1.45 for BMI 30.0 to <35.0, and 1.94 for BMI 35.0 to <40.0.

The nadir of mortality risk was observed at BMI 20 to 22 kg/m2 in studies of healthy never-smokers with the longest duration of follow-up (≥20 years) [21]. While increasing weight is still generally associated with increasing mortality, the BMI range associated with the lowest mortality has been increasing. Among three Danish cohorts, the BMI associated with the lowest all-cause mortality increased from 23.7 kg/m2 in a 1976 through 1978 cohort to 27.0 kg/m2 in a 2003 through 2013 cohort [29].

Controversies: Association between weight and mortality

"Metabolically healthy" patients with obesity — The term "metabolically healthy" patients with obesity and overweight refers to individuals who do not have clear adiposity-associated cardiometabolic abnormalities (ie, hypertension, hypertriglyceridemia, low serum high-density lipoprotein cholesterol, impaired fasting glucose and/or evidence of insulin resistance, diabetes mellitus, abnormal C-reactive protein, or abnormal liver function tests suggesting fatty liver disease) [30].

Despite the lack of metabolic abnormalities in a subset of patients with obesity, there is evidence of increased mortality [31]. In a pooled analysis of four studies with 10-year follow-up, "metabolically healthy" individuals with obesity had an increased risk of mortality compared with metabolically healthy normal-weight individuals [20]. However, in metabolically healthy overweight individuals, the increased risk of mortality did not reach statistical significance, even when the analysis was restricted to studies with at least 10 years of follow-up. Thus, some of the variability in mortality estimates among overweight people may be due to risks that are proportional to excess fat mass; overweight individuals represent a spectrum of risk that is generally lower than individuals with obesity, at least over the short term.

It is evident that obesity varies in its impact on metabolic health and may often require many years to render measurable deleterious effects. In addition, an absence of quantitative impact on current metabolic health does not ensure a lack of impact on mental, social, or overall physical health.

The issue of "metabolically healthy" obesity is discussed in detail elsewhere. (See "Obesity: Association with cardiovascular disease", section on 'Metabolically "healthy" obesity'.)

Obesity paradox — Some studies have concluded that elevated BMI may improve survival in individuals with cardiovascular disease (CVD), primarily congestive heart failure, a phenomenon called the "obesity paradox" [32,33]. However, these studies have not considered body fat distribution. Abdominal (versus gluteal) fat mass is strongly predictive of metabolic disease and mortality when measured by dual-energy x-ray absorptiometry (DXA) [34], waist-to-hip ratio [35], or waist circumference [34]. Thus, people with BMI <25 kg/m2 but with central obesity appear to have an increased mortality risk and should be targeted for lifestyle modification strategies.

In contrast to the many studies reporting that overweight is associated with higher mortality, there are data that suggest lower mortality for those with BMI in the 25 to 30 kg/m2 range [24]. Nevertheless, this was challenged by a large Australian study of 246,314 individuals, again showing the lowest mortality in those with a BMI of 22.5 to 24.99 kg/m2, not BMI 25 to 29.99 kg/m2 [36].

The obesity paradox needs to be discussed not only in the context of body composition assessment (both fat distribution and amount of lean mass) but also considering cardiovascular fitness and duration of obesity [37]. The obesity paradox is also reviewed elsewhere. (See "Obesity: Association with cardiovascular disease", section on 'Obesity paradox'.)

Mortality at low BMI ranges — A separate question is related to outcomes in individuals with low BMI values. The following observations illustrate the range of findings from variably defined patient populations:

In the Prospective Studies Collaboration, subjects with BMI below 22.5 kg/m2 had higher mortality compared with subjects with a BMI of 22.5 to 25 kg/m2 [17]. The excess mortality was predominantly due to smoking-related diseases (respiratory and cancer).

In the analysis of studies from the National Cancer Institute (NCI) Cohort Consortium, mortality risk was higher among participants with BMI below 22.5 kg/m2 (HR 2.02, 95% CI 1.94-2.11 for females with a BMI of 15 to 18.4 kg/m2 compared with 22.5 to 24.9 kg/m2) [22]. However, the increased mortality rate among those with a BMI below 22.5 kg/m2 was lower in those who were healthy and never smoked compared with all participants (HR 1.47 versus 2.02 and 1.37 versus 1.98 for males and females, respectively, with BMI 15 to 18.4 kg/m2 versus 22.5 to 24.9 kg/m2). In addition, the association between underweight and increased mortality among healthy subjects who never smoked was weaker after 15 years of follow-up than after five years of follow-up (HRs 1.21 and 1.73, respectively).

In the Asian Cohort Consortium, subjects with BMI <20.1 kg/m2 had higher mortality than subjects with BMI of 22.6 to 25 kg/m2 (HR approximately 1.17) [28]. When the analysis was limited to those who did not smoke, the elevated risk was attenuated.

A report from the National Health and Nutrition Examination Survey (NHANES) defined underweight as a BMI <18.5 kg/m2, excluding subjects with illness-related weight loss [38], which is also the criterion used by the World Health Organization (WHO). Being underweight was associated with excess mortality (33,746 excess deaths) in both smokers and nonsmokers [38]. (See "Obesity in adults: Prevalence, screening, and evaluation", section on 'BMI-based classifications'.)

These findings, taken together, suggest that the association between a low BMI and increased mortality is probably, in part, an artifact of preexisting disease and/or smoking. Addressing reverse causality suggests a reduced risk of mortality among those with low BMI levels [39].

Cause-specific mortality — The association between BMI and cause-specific mortality was illustrated in the Prospective Studies Collaboration analysis [17]. In the upper BMI range (25 to 50 kg/m2), each 5 kg/m2 increase in BMI was associated with a significant increase in mortality from coronary heart disease (CHD), stroke, diabetes mellitus, chronic kidney disease, and cancer (liver, kidney, breast, endometrial, prostate, and colon). For those with BMI between 30 and 35 kg/m2, median survival was reduced by two to four years; for 40 to 45 kg/m2, it was reduced by 8 to 10 years (similar to the effects of smoking). Years of life lost are highest for people who develop obesity at a younger age and live with obesity longer [2].

Similar findings were noted for cardiovascular mortality (overall CVD, CHD, ischemic stroke, and hemorrhagic stroke) in the Asian Cohort Consortium. Compared with a BMI of 22.5 to 24.9 kg/m2, study participants from China, Taiwan, Singapore, Japan, and Korea with a higher BMI showed a "dose-effect" with a significantly increased risk of total cardiovascular death (HRs 1.09, 1.27, 1.59, 1.74, and 1.97 for BMI ranges 25 to 27.4, 27.5 to 29.9, 30 to 32.4, 32.5 to 34.9, and 35 to 50 kg/m2, respectively) [40].

Overweight during adolescence — Being overweight during adolescence may also increase the risk of premature death as an adult (figure 2). (See "Overview of the health consequences of obesity in children and adolescents", section on 'Adult cardiovascular disease'.)

Trends in cardiovascular risk factors — Using data from NHANES, the mean age- and sex-adjusted BMI increased from 1990 through 2000 to 2017 through 2018, from 28 to 29.8 kg/m2 [41]. During this period, the adjusted prevalence of obesity increased (from 30 to 42 percent), as did the mean hemoglobin A1C (from 5.4 to 5.7 percent).

However, the impact of obesity on CVD appears to have decreased over time, but this appears to be related to more aggressive and effective management of other cardiovascular risk factors. For example, the adjusted 10-year atherosclerotic CVD risk decreased during this period, from 7.6 to 6.5 percent, which likely reflects decreased smoking prevalence and increased use of cholesterol and blood pressure lowering medications [41].

Effect of fitness — Fitness level is also an important factor in individuals with obesity. In a meta-analysis of 10 studies, compared with fit individuals of normal weight, unfit individuals had twice the risk of mortality regardless of BMI [42]. Further, fit individuals with overweight and obesity had similar mortality risks as fit individuals of normal weight. Physical activity and cardiorespiratory fitness are associated with reductions in CVD, including heart failure and coronary heart disease [43]. Additionally, fitness alters the relationship between adiposity and subsequent major CVD outcomes. By contrast, in the Lipids Research Clinics and the Nurses' Health Studies, both physical fitness and adiposity were independent predictors of mortality, and higher levels of physical activity did not negate the association between obesity and mortality [44,45]. (See "Obesity in adults: Role of physical activity and exercise", section on 'Health benefits associated with exercise'.)

MORBIDITY — Obesity and increased central adiposity are associated with increased morbidity in addition to increased mortality [46,47]. In fact, obesity has surpassed smoking as the number one cause of preventable disease and disability [48]. Over 230 comorbidities and complications of obesity have been identified, and weight loss will improve most of these [49]. As an example, in a survey of adults in the United States, individuals with overweight and obesity had a higher risk of hypertension, hypercholesterolemia, and diabetes mellitus compared with normal weight individuals [50]. In addition, in the Nurses' Health and the Health Professionals Studies, the risk of developing a chronic disease (gallstones, hypertension, heart disease, colon cancer, and stroke [in males only]) increased with increasing body mass index (BMI), even in those in the upper half of the healthy weight range (BMI 22.0 to 24.9 kg/m2) (figure 3) [51,52]. While these data suggest that a BMI <22.0 kg/m2 would be ideal, this is difficult to achieve for many individuals. In addition, the majority of people studied were White persons, and therefore these data cannot be directly extrapolated to a general population.

Metabolic risks

Diabetes mellitus

Type 2 diabetes mellitus is strongly associated with obesity. Insulin resistance with hyperinsulinemia is characteristic of obesity and is present before the onset of hyperglycemia. More than 80 percent of cases of type 2 diabetes can be attributed to obesity, which may also account for many diabetes-related deaths. Weight gain after age 18 years in females and after age 20 years in males also increases the risk of type 2 diabetes (figure 4). (See "Pathogenesis of type 2 diabetes mellitus" and "Type 2 diabetes mellitus: Prevalence and risk factors".)

Weight loss of 5 to 7 percent is associated with a decreased risk of type 2 diabetes among individuals with prediabetes [53]. Weight loss of 15 percent can lead to remission of diabetes in nearly half of the people who can achieve this [54]. (See "Prevention of type 2 diabetes mellitus", section on 'Lifestyle intervention' and "Nutritional considerations in type 2 diabetes mellitus".)

Dyslipidemia — Obesity is associated with several deleterious changes in lipid metabolism. Unfavorable obesity-related effects include elevated serum total and low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, and triglycerides, as well as a reduction in serum high-density lipoprotein cholesterol [55]. (See "Inherited disorders of LDL-cholesterol metabolism other than familial hypercholesterolemia", section on 'Prevalence of lipid abnormalities'.)

Central adiposity also plays an important role in the serum lipid abnormalities. (See "Obesity in adults: Prevalence, screening, and evaluation".)

Cardiovascular

Hypertension — Blood pressure is often increased in those with obesity. The risk of hypertension is greatest in subjects with upper body and abdominal obesity. Weight loss in individuals with obesity is associated with a decline in blood pressure. The effect of weight loss in patients with obesity and hypertension is discussed in greater detail elsewhere. (See "Overweight, obesity, and weight reduction in hypertension", section on 'Weight reduction to lower blood pressure'.)

Heart disease — Obesity is also associated with increased risks of coronary heart disease (CHD), heart failure, and, as described above, cardiovascular and all-cause mortality [56]. Weight loss (achieved through lifestyle modification, medication, or surgery) is associated with an improvement in cardiovascular risk factors [57]. (See "Obesity: Association with cardiovascular disease" and "Bariatric surgery for management of obesity: Indications and preoperative preparation".)

Coronary heart disease – Obesity has long been associated with an increased risk for CHD. The risk of CHD in those with overweight and obesity is compounded by the frequent coexistence of other CHD risk factors, such as hypertension, dyslipidemia, and diabetes. Models that adjust for traditional risk factors report an attenuated but statistically significant association between obesity and CHD [58]. The relationship between obesity and CHD is reviewed elsewhere. (See "Obesity: Association with cardiovascular disease", section on 'Obesity and CHD'.)

Heart failure – There is an important association between obesity and heart failure. There are a number of mechanisms by which obesity could predispose to heart failure (figure 5). The association between obesity and heart failure is discussed in detail elsewhere. (See "Obesity: Association with cardiovascular disease", section on 'Heart failure'.)

Myocardial steatosis – One potential mechanism for heart disease in obesity is thought to be excessive lipid accumulation in the myocardium [59,60].

Atrial fibrillation – Individuals with obesity (BMI >30 kg/m2) are significantly more likely to develop atrial fibrillation than those with a normal BMI (<25 kg/m2). (See "Epidemiology, risk factors, and prevention of atrial fibrillation", section on 'Obesity' and "Obesity: Association with cardiovascular disease", section on 'Atrial fibrillation'.)

Stroke — Obesity is associated with an increased risk of stroke, and stroke risk is mitigated by weight loss. (See "Overview of primary prevention of cardiovascular disease".)

Venous thromboembolism — Obesity has been associated with an increased risk of venous thromboembolism, including deep vein thrombosis and pulmonary embolism. This topic is reviewed in detail elsewhere. (See "Overview of the causes of venous thrombosis", section on 'Obesity'.)

Cancer — Excess weight is associated with an increased risk of multiple cancer types. Overweight and obesity were estimated to cause 40 percent of all cancers in the United States in 2014 [61]. Childhood obesity increases the risk of cancer in adulthood [62]. (See "Overview of the health consequences of obesity in children and adolescents", section on 'Cancer'.)

In addition, obesity and overweight may increase the likelihood of dying from cancer. The mechanisms contributing to higher cancer incidence and mortality may include alterations in sex hormone metabolism, insulin and insulin-like growth factor levels, and adipokine pathways [63,64].

The rates of cancer related to excess weight are higher in females than males [61]. Although the strength of the association and the types of cancers vary somewhat across studies, multiple meta-analyses found strong evidence supporting the association between obesity and the following cancers [65,66]:

Endometrial (see "Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Obesity')

Kidney (see "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Obesity')

Gastric cardia (see "Risk factors for gastric cancer", section on 'Obesity')

Colon (see "Epidemiology and risk factors for colorectal cancer", section on 'Obesity')

Rectum (see "Epidemiology and risk factors for colorectal cancer", section on 'Obesity')

Biliary tract (see "Epidemiology, risk factors, anatomy, and pathology of cholangiocarcinoma", section on 'Obesity')

Pancreas (see "Epidemiology and nonfamilial risk factors for exocrine pancreatic cancer", section on 'Obesity and physical inactivity')

Breast (in females who had never taken hormones) (see "Factors that modify breast cancer risk in women", section on 'Weight and body fat in postmenopausal women')

Esophageal adenocarcinoma (see "Epidemiology and pathobiology of esophageal cancer", section on 'Obesity and metabolic syndrome')

Ovarian (see "Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: Incidence and risk factors", section on 'Obesity')

Multiple myeloma (see "Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Epidemiology')

Hepatocellular carcinoma (see "Epidemiology and risk factors for hepatocellular carcinoma", section on 'Obesity')

Meningioma (see "Epidemiology, pathology, clinical features, and diagnosis of meningioma", section on 'Others')

Musculoskeletal

Osteoarthritis — The incidence of osteoarthritis is increased in subjects with obesity and accounts for a major component of the cost of obesity [67]. (See "Epidemiology and risk factors for osteoarthritis", section on 'Obesity' and "Comorbidities that impact management of osteoarthritis", section on 'Obesity'.)

Gout — The risk of developing gouty arthritis increases with body weight and with the amount of weight gain during adulthood. The influence of BMI on hyperuricemia and gout is discussed in more detail elsewhere. (See "Nonpharmacologic strategies for the prevention and treatment of gout".)

Gastrointestinal

Hepatobiliary disease — Obesity is associated with an increased risk of gallbladder disease and nonalcoholic fatty liver disease. In a meta-analysis of 17 studies with 55,670 individuals, the risk of gallbladder disease increased even within the normal BMI range [68]. Obesity affects the hepatobiliary system, primarily by causing cholelithiasis (figure 3). Weight loss has also been associated with cholelithiasis and cholecystitis, especially when weight loss is rapid. (See "Gallstones: Epidemiology, risk factors and prevention", section on 'Diet and lifestyle factors' and "Pathogenesis of nonalcoholic fatty liver disease".)

GERD/gastrointestinal cancer — Obesity is a risk factor for gastrointestinal-related disease, including gastroesophageal reflux disease (GERD), erosive esophagitis, esophageal adenocarcinoma, and gastric cancer [69]. (See "Epidemiology and pathobiology of esophageal cancer", section on 'Obesity and metabolic syndrome' and "Risk factors for gastric cancer", section on 'Obesity'.)

Reproductive effects — In females, obesity is associated with several reproductive disorders including:

Infertility (See "Female infertility: Causes", section on 'Ovulatory disorders' and "Natural fertility and impact of lifestyle factors", section on 'Overweight and obesity'.)

Abnormal uterine bleeding (See "Causes of female genital tract bleeding", section on 'Ovulatory dysfunction (AUB-O)'.)

Endometrial hyperplasia/carcinoma (See "Endometrial hyperplasia: Clinical features, diagnosis, and differential diagnosis", section on 'Risk factors' and "Endometrial carcinoma: Epidemiology, risk factors, and prevention", section on 'Risk factors'.)

Anovulatory cycles/polycystic ovarian syndrome (See "Diagnosis of polycystic ovary syndrome in adults", section on 'Clinical features'.)

Uterine fibroids (See "Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history", section on 'Obesity'.)

Endometriosis (See "Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact", section on 'Risk factors'.)

Sexual dysfunction (See "Overview of sexual dysfunction in females: Epidemiology, risk factors, and evaluation".)

Pregnant people with obesity are also at increased risk for a number of maternal and perinatal complications, and the risks are amplified with increasing degrees of maternal obesity [70]. (See "Obesity in pregnancy: Complications and maternal management".)

In males, obesity is associated with infertility and is an independent risk factor erectile dysfunction. (See "Causes of male infertility", section on 'Systemic disorders' and "Epidemiology and etiologies of male sexual dysfunction".)

Genitourinary

Chronic kidney disease — Obesity is associated with multiple other conditions that are known to cause compromised kidney function, including hypertension, diabetes mellitus, and the metabolic syndrome. A high BMI is one of the strongest risk factors for chronic kidney disease [71]. Data from the Hypertension Detection and Follow-Up Program and the Multiphasic Health Testing Services Program suggest that obesity may be independently associated with the risk of developing chronic kidney disease [70,72,73]. By contrast, however, the Framingham Offspring study did not observe obesity as an independent risk factor after adjustment for diabetes, systolic blood pressure, current smoking status, and high-density lipoprotein cholesterol level [74]. A 2021 study based upon 2005 to 2016 National Health and Nutrition Examination Survey (NHANES) data showed that metabolic syndrome, rather than obesity, was associated with chronic kidney disease. [75]. The relationship between obesity and chronic kidney disease is complex and likely bidirectional [76].

Focal segmental glomerulosclerosis and obesity-related glomerulopathy (glomerular enlargement and mesangial expansion), both of which are associated with proteinuria, have been described in patients with severe obesity. Obesity-related glomerulopathy may be reversible with weight loss [77]. This is reviewed in detail elsewhere. (See "Epidemiology of chronic kidney disease" and "Focal segmental glomerulosclerosis: Pathogenesis", section on 'Obesity'.)

Kidney stones — Obesity and weight gain during adulthood appear to be associated with an increased risk of kidney stones [78,79]. (See "Kidney stones in adults: Epidemiology and risk factors".)

Urinary incontinence — In females, overweight and obesity are important risk factors for urinary incontinence. (See "Female urinary incontinence: Evaluation", section on 'Risk factors'.)

Dialysis and kidney transplantation — Obesity poses additional challenges to the care of the dialysis patient, including difficulties in obtaining vascular access, higher rates of catheter malfunction and peritonitis, the need for longer and/or more frequent dialysis to achieve adequate clearance, and increased metabolic complications. Over 60 percent of kidney transplant patients have overweight or obesity, and obesity is a barrier to kidney transplantation [80].(See "Patient evaluation prior to placement of hemodialysis arteriovenous access" and "Kidney transplantation in adults: Evaluation of the potential kidney transplant recipient", section on 'Obesity'.)

Psychosocial function

Stigma of obesity — Those with obesity are often exposed to disapproval because of their weight. This stigma is seen in education, employment, and health care, among other areas [81].

In the Coronary Artery Risk Development in Young Adults (CARDIA) study, weight discrimination reported among those who completed the 25-year follow-up examination was highest for White females (30.2 percent), lowest for White males (12 percent), and intermediate for Black males and females [82]. People with obesity are also discriminated against in hiring and more so for more physically demanding occupations [83,84].

Depression — Depression has also been seen in association with severe obesity, particularly among younger and female individuals [85].

Dementia — Obesity may be associated with an increased risk of the development of dementia. (See "Risk factors for cognitive decline and dementia", section on 'Obesity and body mass index'.)

Respiratory system

Obstructive sleep apnea — Sleep apnea is the most important respiratory problem associated with obesity and diabetes, with several studies confirming that obesity is a major risk factor for the development of obstructive sleep apnea [86,87]. (See "Clinical presentation and diagnosis of obstructive sleep apnea in adults" and "Obstructive sleep apnea and cardiovascular disease in adults".)

Asthma — Experimental models, prospective cohort studies, population-based case-control studies, and a meta-analysis suggest that patients with an elevated BMI are at increased risk for developing asthma [88]. This risk may be greater for nonallergic asthma than allergic asthma. Further, there is an apparent dose-dependent effect such that the greater the BMI, the greater the risk of asthma [89]. This is reviewed in detail elsewhere. (See "Obesity and asthma".)

Obesity hypoventilation syndrome — Other alterations in pulmonary function may occur, including higher residual lung volume associated with increased abdominal pressure on the diaphragm, decreased lung compliance and increased chest wall impedance, ventilation-perfusion abnormalities, reduced strength and endurance of respiratory muscles, and depressed ventilatory drive [90]. (See "Epidemiology and pathogenesis of obesity hypoventilation syndrome".)

Infection — Obesity is associated with an increased susceptibility to infections, including postoperative, nosocomial, respiratory, and skin and soft tissue infections [91-94]. Although the effect of obesity on the immune system is not clearly defined, it appears to have an effect independent of coexisting risk factors (eg, diabetes) [95,96].

Influenza — Individuals with obesity are more likely than normal-weight individuals to have respiratory complications during influenza season and are more likely to be hospitalized with influenza [95-97]. (See "Seasonal influenza in nonpregnant adults: Treatment".)

COVID-19 — Observational data associate obesity with increased morbidity and mortality from coronavirus disease 2019 (COVID-19) [98-102]. (See "COVID-19: Clinical features", section on 'Risk factors for severe illness'.)

Representative studies include:

In a study including two cohorts (approximately 2500) patients hospitalized with COVID-19 in New York City, obesity was associated with an increased risk of intubation or death among adults less than 65 years of age [101].

In a study including almost 7000 adults with COVID-19, there was a J-shaped association between BMI and risk of death at 21 days [103]. Patients with BMIs of 40 to 44 kg/m2 and >45 kg/m2 had an increased risk of death compared with patients with a BMI of 18.5 to 24 kg/m2 (relative risk [RR] 2.68, 95% CI 1.43-5.04 and 4.18, 95% CI 2.12-8.26) respectively.

In a pooled analysis of 75 studies, individuals with obesity had a 46 percent higher risk for being COVID-19 positive, a 113 percent higher risk of being hospitalized, a 74 percent higher risk for intensive care unit (ICU) admission, and a 48 percent increased mortality [102].

Skin changes — Several changes in the skin are associated with obesity.

Stretch marks (striae) (picture 1) are common and reflect the tension on the skin from expanding subcutaneous deposits of fat.

Acanthosis nigricans, with deepening pigmentation around the neck, axilla (picture 2), knuckles, and extensor surfaces, may occur in connection with obesity. The proposed cause of this hyperpigmentation, as well as skin tags, is sustained hyperinsulinemia [104]. (See "Insulin resistance: Definition and clinical spectrum".)

Hirsutism in females may result from increased production of testosterone, which is often associated with visceral obesity. (See "Pathophysiology and causes of hirsutism".)

Obesity in offspring — Maternal obesity is a risk factor for the development of obesity among offspring, as well as other chronic conditions such dyslipidemia, type 2 diabetes mellitus, and hypertension [105,106]. The mechanisms are likely multifactorial. This is reviewed in detail elsewhere. (See "Definition, epidemiology, and etiology of obesity in children and adolescents", section on 'Metabolic programming'.)

HEALTH CARE COSTS OF OBESITY — The treatment of obesity and obesity-related conditions represents an enormous economic burden [47,107-112]. In addition to direct health care expenses, there are other costs, including lost work productivity and lower household income; in 2017, obesity cost the United States an estimated USD $1.4 trillion [113].

In the Swedish Obesity Study, individuals with obesity were three times as likely to draw a disability pension, used twice the number of sick days, and had higher annual drug costs compared with individuals without obesity [114].

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Obesity in adults".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Weight loss treatments (The Basics)" and "Patient education: Health risks of obesity (The Basics)")

Beyond the Basics topics (see "Patient education: Losing weight (Beyond the Basics)" and "Patient education: Weight loss surgery and procedures (Beyond the Basics)")

SUMMARY AND RECOMMENDATIONS

Weight and mortality – Obesity is associated with excess morbidity and mortality. Although imperfect, calculation of the body mass index (BMI) is widely accepted for the determination of underweight, normal weight, overweight, and obesity. Overweight is defined as a BMI of 25 to 29.9 kg/m2, obesity as a BMI of >30 kg/m2, and severe obesity is defined as a BMI >40 kg/m2.

In general, greater BMI (calculated as weight [in kg] divided by height [in m2]) (calculator 1), is associated with increased all-cause and cardiovascular mortality (figure 1). (See 'Introduction' above and 'Mortality' above.)

Weight-related morbidities – Obesity and increased central fat are associated with type 2 diabetes mellitus, hypertension, heart disease (including coronary heart disease [CHD], heart failure, atrial fibrillation), stroke, obstructive sleep apnea, venous thromboembolism, cancer, osteoarthritis, hepatobiliary disease, gastroesophageal reflux, asthma, chronic kidney disease, and other chronic conditions. Even modest weight loss improves these comorbidities. (See 'Morbidity' above.)

Obesity affects psychosocial function as individuals with obesity are often exposed to public disapproval. This stigma is seen in education, employment, and health care, among other areas. (See 'Stigma of obesity' above.)

Health care costs – The treatment of obesity-related conditions represents an enormous economic burden. In addition to direct health care expenses, there are other costs, including lost work productivity and lower household income. (See 'Health care costs of obesity' above.)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges George Bray, MD, who contributed to an earlier version of this topic review.

  1. Bray GA. The Battle of the Bulge: A History of Obesity Research, Dorrance, 2007.
  2. Grover SA, Kaouache M, Rempel P, et al. Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol 2015; 3:114.
  3. Olshansky SJ, Passaro DJ, Hershow RC, et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med 2005; 352:1138.
  4. Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med 2003; 138:24.
  5. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju ShN, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 2016; 388:776.
  6. McTigue K, Larson JC, Valoski A, et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 2006; 296:79.
  7. GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med 2017; 377:13.
  8. Chen C, Ye Y, Zhang Y, et al. Weight change across adulthood in relation to all cause and cause specific mortality: prospective cohort study. BMJ 2019; 367:l5584.
  9. Bhaskaran K, Dos-Santos-Silva I, Leon DA, et al. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK. Lancet Diabetes Endocrinol 2018; 6:944.
  10. Yan LL, Daviglus ML, Liu K, et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 2006; 295:190.
  11. Gu D, He J, Duan X, et al. Body weight and mortality among men and women in China. JAMA 2006; 295:776.
  12. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355:763.
  13. Jee SH, Sull JW, Park J, et al. Body-mass index and mortality in Korean men and women. N Engl J Med 2006; 355:779.
  14. Freedman DM, Ron E, Ballard-Barbash R, et al. Body mass index and all-cause mortality in a nationwide US cohort. Int J Obes (Lond) 2006; 30:822.
  15. Price GM, Uauy R, Breeze E, et al. Weight, shape, and mortality risk in older persons: elevated waist-hip ratio, not high body mass index, is associated with a greater risk of death. Am J Clin Nutr 2006; 84:449.
  16. Pischon T, Boeing H, Hoffmann K, et al. General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359:2105.
  17. Prospective Studies Collaboration, Whitlock G, Lewington S, et al. Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 2009; 373:1083.
  18. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298:2028.
  19. Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes. N Engl J Med 2014; 370:233.
  20. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med 2013; 159:758.
  21. Aune D, Sen A, Prasad M, et al. BMI and all cause mortality: systematic review and non-linear dose-response meta-analysis of 230 cohort studies with 3.74 million deaths among 30.3 million participants. BMJ 2016; 353:i2156.
  22. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363:2211.
  23. Boggs DA, Rosenberg L, Cozier YC, et al. General and abdominal obesity and risk of death among black women. N Engl J Med 2011; 365:901.
  24. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 2013; 309:71.
  25. Costanzo P, Cleland JG, Pellicori P, et al. The obesity paradox in type 2 diabetes mellitus: relationship of body mass index to prognosis: a cohort study. Ann Intern Med 2015; 162:610.
  26. Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999; 341:1097.
  27. Fontaine KR, McCubrey R, Mehta T, et al. Body mass index and mortality rate among Hispanic adults: a pooled analysis of multiple epidemiologic data sets. Int J Obes (Lond) 2012; 36:1121.
  28. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med 2011; 364:719.
  29. Afzal S, Tybjærg-Hansen A, Jensen GB, Nordestgaard BG. Change in Body Mass Index Associated With Lowest Mortality in Denmark, 1976-2013. JAMA 2016; 315:1989.
  30. Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch Intern Med 2008; 168:1617.
  31. Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically Healthy Obese and Incident Cardiovascular Disease Events Among 3.5 Million Men and Women. J Am Coll Cardiol 2017; 70:1429.
  32. Lavie CJ, Milani RV, Artham SM, et al. The obesity paradox, weight loss, and coronary disease. Am J Med 2009; 122:1106.
  33. Lavie CJ, Sharma A, Alpert MA, et al. Update on Obesity and Obesity Paradox in Heart Failure. Prog Cardiovasc Dis 2016; 58:393.
  34. Padwal R, Leslie WD, Lix LM, Majumdar SR. Relationship Among Body Fat Percentage, Body Mass Index, and All-Cause Mortality: A Cohort Study. Ann Intern Med 2016; 164:532.
  35. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, et al. Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann Intern Med 2015; 163:827.
  36. Joshy G, Korda RJ, Bauman A, et al. Investigation of methodological factors potentially underlying the apparently paradoxical findings on body mass index and all-cause mortality. PLoS One 2014; 9:e88641.
  37. Carbone S, Canada JM, Billingsley HE, et al. Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag 2019; 15:89.
  38. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293:1861.
  39. Garcia GR 3rd, Coleman NC, Pond ZA, Pope CA 3rd. Shape of BMI-Mortality Risk Associations: Reverse Causality and Heterogeneity in a Representative Cohort of US Adults. Obesity (Silver Spring) 2021; 29:755.
  40. Chen Y, Copeland WK, Vedanthan R, et al. Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ 2013; 347:f5446.
  41. He J, Zhu Z, Bundy JD, et al. Trends in Cardiovascular Risk Factors in US Adults by Race and Ethnicity and Socioeconomic Status, 1999-2018. JAMA 2021; 326:1286.
  42. Barry VW, Baruth M, Beets MW, et al. Fitness vs. fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 2014; 56:382.
  43. Lavie CJ, Carbone S, Kachur S, et al. Effects of Physical Activity, Exercise, and Fitness on Obesity-Related Morbidity and Mortality. Curr Sports Med Rep 2019; 18:292.
  44. Stevens J, Cai J, Evenson KR, Thomas R. Fitness and fatness as predictors of mortality from all causes and from cardiovascular disease in men and women in the lipid research clinics study. Am J Epidemiol 2002; 156:832.
  45. Hu FB, Willett WC, Li T, et al. Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med 2004; 351:2694.
  46. Haslam DW, James WP. Obesity. Lancet 2005; 366:1197.
  47. Wang YC, McPherson K, Marsh T, et al. Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 2011; 378:815.
  48. Mather M, Scommegna P. Up to half of US premature deaths are preventable; behavioral factors key. Population Reference Bureau 2015. Available at: https://www.prb.org/resources/up-to-half-of-u-s-premature-deaths-are-preventable-behavioral-factors-key/ (Accessed on May 16, 2022).
  49. Rueda-Clausen CF, Ogunleye AA, Sharma AM. Health Benefits of Long-Term Weight-Loss Maintenance. Annu Rev Nutr 2015; 35:475.
  50. Nguyen NT, Magno CP, Lane KT, et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207:928.
  51. Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med 2001; 161:1581.
  52. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341:427.
  53. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.
  54. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018; 391:541.
  55. Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol 2006; 26:968.
  56. Aune D, Sen A, Norat T, et al. Body Mass Index, Abdominal Fatness, and Heart Failure Incidence and Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies. Circulation 2016; 133:639.
  57. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004; 110:2952.
  58. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011; 377:1085.
  59. McGavock JM, Victor RG, Unger RH, et al. Adiposity of the heart, revisited. Ann Intern Med 2006; 144:517.
  60. Mizunami M, Tateda H. Dynamic relationship between the slow potential and spikes in cockroach ocellar neurons. J Gen Physiol 1988; 91:703.
  61. Steele CB, Thomas CC, Henley SJ, et al. Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005-2014. MMWR Morb Mortal Wkly Rep 2017; 66:1052.
  62. Weihrauch-Blüher S, Schwarz P, Klusmann JH. Childhood obesity: increased risk for cardiometabolic disease and cancer in adulthood. Metabolism 2019; 92:147.
  63. Gallagher EJ, LeRoith D. Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality. Physiol Rev 2015; 95:727.
  64. Scappaticcio L, Maiorino MI, Bellastella G, et al. Insights into the relationships between diabetes, prediabetes, and cancer. Endocrine 2017; 56:231.
  65. Kyrgiou M, Kalliala I, Markozannes G, et al. Adiposity and cancer at major anatomical sites: umbrella review of the literature. BMJ 2017; 356:j477.
  66. Fang X, Wei J, He X, et al. Quantitative association between body mass index and the risk of cancer: A global Meta-analysis of prospective cohort studies. Int J Cancer 2018; 143:1595.
  67. Kulkarni K, Karssiens T, Kumar V, Pandit H. Obesity and osteoarthritis. Maturitas 2016; 89:22.
  68. Aune D, Norat T, Vatten LJ. Body mass index, abdominal fatness and the risk of gallbladder disease. Eur J Epidemiol 2015; 30:1009.
  69. Chang P, Friedenberg F. Obesity and GERD. Gastroenterol Clin North Am 2014; 43:161.
  70. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144:21.
  71. Kovesdy CP, Furth SL, Zoccali C, World Kidney Day Steering Committee. Obesity and kidney disease: hidden consequences of the epidemic. J Nephrol 2017; 30:1.
  72. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005; 46:587.
  73. Ferris M, Hogan SL, Chin H, et al. Obesity, albuminuria, and urinalysis findings in US young adults from the Add Health Wave III study. Clin J Am Soc Nephrol 2007; 2:1207.
  74. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis 2008; 52:39.
  75. Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Metabolic Syndrome, and Not Obesity, Is Associated with Chronic Kidney Disease. Am J Nephrol 2021; 52:666.
  76. Lakkis JI, Weir MR. Obesity and Kidney Disease. Prog Cardiovasc Dis 2018; 61:157.
  77. Shen WW, Chen HM, Chen H, et al. Obesity-related glomerulopathy: body mass index and proteinuria. Clin J Am Soc Nephrol 2010; 5:1401.
  78. Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA 2005; 293:455.
  79. Kim S, Chang Y, Yun KE, et al. Metabolically healthy and unhealthy obesity phenotypes and risk of renal stone: a cohort study. Int J Obes (Lond) 2019; 43:852.
  80. Diwan TS, Cuffy MC, Linares-Cervantes I, Govil A. Impact of obesity on dialysis and transplant and its management. Semin Dial 2020; 33:279.
  81. Puhl RM, Himmelstein MS, Pearl RL. Weight stigma as a psychosocial contributor to obesity. Am Psychol 2020; 75:274.
  82. Dutton GR, Lewis TT, Durant N, et al. Perceived weight discrimination in the CARDIA study: differences by race, sex, and weight status. Obesity (Silver Spring) 2014; 22:530.
  83. Flint SW, Čadek M, Codreanu SC, et al. Obesity Discrimination in the Recruitment Process: "You're Not Hired!". Front Psychol 2016; 7:647.
  84. Ul-Haq Z, Mackay DF, Fenwick E, Pell JP. Meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the SF-36. Obesity (Silver Spring) 2013; 21:E322.
  85. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003; 163:2058.
  86. Grewal G, Joshi GP. Obesity and Obstructive Sleep Apnea in the Ambulatory Patient. Anesthesiol Clin 2019; 37:215.
  87. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolic risk in obesity and the metabolic syndrome. J Am Coll Cardiol 2013; 62:569.
  88. Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol 2018; 141:1169.
  89. Koebnick C, Fischer H, Daley MF, et al. Interacting effects of obesity, race, ethnicity and sex on the incidence and control of adult-onset asthma. Allergy Asthma Clin Immunol 2016; 12:50.
  90. Muzumdar H, Rao M. Pulmonary dysfunction and sleep apnea in morbid obesity. Pediatr Endocrinol Rev 2006; 3 Suppl 4:579.
  91. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006; 6:438.
  92. Tsai AG, Wadden TA. In the clinic: obesity. Ann Intern Med 2013; 159:ITC3.
  93. Farmakiotis D. Obesity and serious infections. Ann Intern Med 2013; 159:859.
  94. Power K, Davies MM, Hargest R, et al. A case-control study of risk factors for wound infection in a colorectal unit. Ann R Coll Surg Engl 2014; 96:37.
  95. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis 2011; 53:413.
  96. Karki S, Muscatello DJ, Banks E, et al. Association between body mass index and laboratory-confirmed influenza in middle aged and older adults: a prospective cohort study. Int J Obes (Lond) 2018; 42:1480.
  97. Almond MH, Edwards MR, Barclay WS, Johnston SL. Obesity and susceptibility to severe outcomes following respiratory viral infection. Thorax 2013; 68:684.
  98. Lighter J, Phillips M, Hochman S, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis 2020; 71:896.
  99. Caussy C, Pattou F, Wallet F, Simon C. High prevalence of obesity among adult inpatients wtih severe COVID-19 in initial and validation population; a cross sectional French study. Lancet Diabetes Endocrinol 2020.
  100. Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity (Silver Spring) 2020; 28:1195.
  101. Anderson MR, Geleris J, Anderson DR, et al. Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection : A Retrospective Cohort Study. Ann Intern Med 2020; 173:782.
  102. Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. Obes Rev 2020; 21:e13128.
  103. Tartof SY, Qian L, Hong V, et al. Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization. Ann Intern Med 2020; 173:773.
  104. Maitra SK, Rowland Payne CM. The obesity syndrome and acanthosis nigricans. Acanthosis nigricans is a common cosmetic problem providing epidemiological clues to the obesity syndrome, the insulin-resistance syndrome, the thrifty metabolism, dyslipidaemia, hypertension and diabetes mellitus type II. J Cosmet Dermatol 2004; 3:202.
  105. Reynolds RM. Excess maternal weight gain during pregnancy is associated with overweight/obesity in offspring at age 16 years, but maternal pre-pregnancy obesity has a greater effect. Evid Based Nurs 2013; 16:43.
  106. Reynolds RM, Allan KM, Raja EA, et al. Maternal obesity during pregnancy and premature mortality from cardiovascular event in adult offspring: follow-up of 1 323 275 person years. BMJ 2013; 347:f4539.
  107. Finkelstein EA, Trogdon JG, Brown DS, et al. The lifetime medical cost burden of overweight and obesity: implications for obesity prevention. Obesity (Silver Spring) 2008; 16:1843.
  108. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 2004; 292:2471.
  109. Quesenberry CP Jr, Caan B, Jacobson A. Obesity, health services use, and health care costs among members of a health maintenance organization. Arch Intern Med 1998; 158:466.
  110. Daviglus ML, Liu K, Yan LL, et al. Relation of body mass index in young adulthood and middle age to Medicare expenditures in older age. JAMA 2004; 292:2743.
  111. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894:i.
  112. Tremmel M, Gerdtham UG, Nilsson PM, Saha S. Economic Burden of Obesity: A Systematic Literature Review. Int J Environ Res Public Health 2017; 14.
  113. Waters H, DeVol R. Weighing down America: The health and economic impact of obesity. Milken Institute 2016. Available at: https://milkeninstitute.org/report/weighing-down-america-health-and-economic-impact-obesity (Accessed on June 12, 2019).
  114. Narbro K, Agren G, Jonsson E, et al. Pharmaceutical costs in obese individuals: comparison with a randomly selected population sample and long-term changes after conventional and surgical treatment: the SOS intervention study. Arch Intern Med 2002; 162:2061.
Topic 5370 Version 56.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟